A detailed history of Wells Fargo & Company transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 703,941 shares of HALO stock, worth $34.5 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
703,941
Previous 646,255 8.93%
Holding current value
$34.5 Million
Previous $33.8 Million 19.02%
% of portfolio
0.01%
Previous 0.01%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$51.3 - $64.42 $2.96 Million - $3.72 Million
57,686 Added 8.93%
703,941 $40.3 Million
Q2 2024

Aug 13, 2024

BUY
$37.81 - $52.4 $339,495 - $470,499
8,979 Added 1.41%
646,255 $33.8 Million
Q1 2024

May 10, 2024

SELL
$33.68 - $41.95 $653,661 - $814,165
-19,408 Reduced 2.96%
637,276 $25.9 Million
Q4 2023

Feb 09, 2024

SELL
$33.32 - $42.1 $604,924 - $764,325
-18,155 Reduced 2.69%
656,684 $24.3 Million
Q3 2023

Nov 13, 2023

SELL
$36.46 - $44.03 $842,882 - $1.02 Million
-23,118 Reduced 3.31%
674,839 $25.8 Million
Q2 2023

Aug 15, 2023

BUY
$30.28 - $38.74 $2.26 Million - $2.89 Million
74,621 Added 11.97%
697,957 $25.2 Million
Q1 2023

May 12, 2023

BUY
$32.86 - $55.7 $5.3 Million - $8.99 Million
161,334 Added 34.92%
623,336 $23.8 Million
Q4 2022

Feb 13, 2023

SELL
$40.06 - $59.44 $6.76 Million - $10 Million
-168,835 Reduced 26.76%
462,002 $26.3 Million
Q3 2022

Nov 14, 2022

BUY
$38.53 - $51.78 $18 Million - $24.2 Million
467,998 Added 287.4%
630,837 $24.9 Million
Q2 2022

Aug 12, 2022

SELL
$37.35 - $48.3 $10.3 Million - $13.3 Million
-276,326 Reduced 62.92%
162,839 $7.17 Million
Q1 2022

May 16, 2022

SELL
$31.97 - $41.06 $1.34 Million - $1.73 Million
-42,070 Reduced 8.74%
439,165 $17.5 Million
Q4 2021

Feb 14, 2022

SELL
$31.82 - $40.75 $27.7 Million - $35.5 Million
-871,292 Reduced 64.42%
481,235 $19.4 Million
Q3 2021

Nov 15, 2021

BUY
$38.47 - $46.42 $8.07 Million - $9.74 Million
209,853 Added 18.37%
1,352,527 $55 Million
Q2 2021

Aug 16, 2021

BUY
$38.84 - $51.31 $1.6 Million - $2.11 Million
41,104 Added 3.73%
1,142,674 $51.9 Million
Q1 2021

May 13, 2021

SELL
$39.51 - $51.45 $2.04 Million - $2.66 Million
-51,703 Reduced 4.48%
1,101,570 $45.9 Million
Q4 2020

Feb 09, 2021

SELL
$25.81 - $43.62 $3.7 Million - $6.25 Million
-143,304 Reduced 11.05%
1,153,273 $49.3 Million
Q3 2020

Nov 05, 2020

BUY
$25.74 - $29.63 $2.27 Million - $2.61 Million
88,021 Added 7.28%
1,296,577 $34.1 Million
Q2 2020

Aug 13, 2020

BUY
$16.25 - $26.81 $1.61 Million - $2.65 Million
98,838 Added 8.91%
1,208,556 $32.4 Million
Q1 2020

May 14, 2020

BUY
$13.9 - $21.83 $15.4 Million - $24.2 Million
1,109,718 New
1,109,718 $20 Million

Others Institutions Holding HALO

About HALOZYME THERAPEUTICS, INC.


  • Ticker HALO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 139,288,992
  • Market Cap $6.83B
  • Description
  • Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...
More about HALO
Track This Portfolio

Track Wells Fargo & Company Portfolio

Follow Wells Fargo & Company and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.